AGLE Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (27 nov 2023 @ 22:00):

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases...

Stats
Dagens volum	43 238.00
Gjennomsnittsvolum	59 537.00
Markedsverdi	48.63M
EPS	$0 ( 2024-03-07 )
Neste inntjeningsdato	( $0 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.162
ATR14	$2.39 (12.36%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-29	Fairmount Funds Management Llc	Buy	406 038	Common Stock
2023-12-29	Fairmount Funds Management Llc	Sell	3 435 480	Common Stock
2023-12-22	Burrows Scott L	Buy	134 953	Common Stock
2023-12-07	Fairmount Funds Management Llc	Buy	16 667	Series B Preferred Stock
2023-11-22	Albers Jeffrey W.	Buy	50 000	Stock Option (Right to Buy)

INSIDER POWER
-5.27
Last 85 transactions
Buy: 64 136 392 \| Sell: 71 129 759

Volum Korrelasjon

Lang: 0.44 (neutral)

Kort: -0.73 (moderate negative)

Signal:(64.735) Neutral

Aeglea Bio Therapeutics Korrelasjon

10 Mest positive korrelasjoner
GAINL	0.987
RETA	0.975
PRVB	0.967
ULBI	0.966
RDUS	0.964
SQL	0.96
HURN	0.948
CSSE	0.946
SONN	0.945
SGMO	0.945

10 Mest negative korrelasjoner
BOCH	-0.967
LMRK	-0.964
SBNYP	-0.962
SHSP	-0.956
TIOA	-0.944
MSDA	-0.941
ANIK	-0.939
MSDAU	-0.938
SKYA	-0.938
QADA	-0.937

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Aeglea Bio Therapeutics Korrelasjon - Valuta/Råvare

0.39
( neutral )

0.32
( neutral )

-0.40
( neutral )

0.44
( neutral )

-0.41
( neutral )

Aeglea Bio Therapeutics Økonomi

Annual	2022
Omsetning:	$2.33M
Bruttogevinst:	$2.33M (100.00 %)
EPS:	$-24.86

FY	2022
Omsetning:	$2.33M
Bruttogevinst:	$2.33M (100.00 %)
EPS:	$-24.86

FY	2021
Omsetning:	$18.74M
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-1.233

FY	2020
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-1.520

Financial Reports:

No articles found.

Aeglea Bio Therapeutics

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.